Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD5335 (AstraZeneca, 1841df)
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AZD5335 is an investigational antibody-drug conjugate (ADC) developed by AstraZeneca that specifically targets the Six-Transmembrane Epithelial Antigen of the Prostate 2 (STEAP2). STEAP2 is a cell-surface protein highly expressed in prostate cancer, particularly in metastatic adenocarcinoma and castration-resistant forms, while exhibiting minimal expression in normal tissues. The ADC consists of a humanized anti-STEAP2 monoclonal antibody conjugated to a cytotoxic topoisomerase I inhibitor payload (an exatecan derivative) via a protease-cleavable linker. Upon binding to STEAP2 on the tumor cell surface, the complex is internalized, and the payload is released within the lysosome, leading to DNA damage and subsequent apoptosis. AZD5335 is currently being evaluated in Phase 1/2 clinical trials for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
- Other names
- STEAP2-targeting antibody-drug conjugateSTEAP-2-targeting antibody-drug conjugateSTEAP 2-targeting antibody-drug conjugateSTEAP2 ADCSTEAP-2 ADCSTEAP 2 ADC
02
Targets
STEAP2 (Six-transmembrane epithelial antigen of the prostate 2)
Beyond the preview
Go deeper on AZD5335 (AstraZeneca, 1841df).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD5335 (AstraZeneca, 1841df).